-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HEVgf/XtER9rSX372jgxA8QDn1K+qvrSovaAl2l5v3N7RmaAPYUq+GZ/onM/EuEu TXnvYP6w82BaEsnejTCjCg== 0001104659-09-050810.txt : 20090820 0001104659-09-050810.hdr.sgml : 20090820 20090820154633 ACCESSION NUMBER: 0001104659-09-050810 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506 FILED AS OF DATE: 20090820 DATE AS OF CHANGE: 20090820 EFFECTIVENESS DATE: 20090820 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LIMERICK BIOPHARMA INC CENTRAL INDEX KEY: 0001358877 IRS NUMBER: 061735053 STATE OF INCORPORATION: CA FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-88136 FILM NUMBER: 091026636 BUSINESS ADDRESS: STREET 1: 601 GATEWAY BOULEVARD STREET 2: #700 CITY: SO. SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-742-0110 MAIL ADDRESS: STREET 1: 601 GATEWAY BOULEVARD STREET 2: #700 CITY: SO. SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: LIMERICK NEUROSCIENES INC DATE OF NAME CHANGE: 20060410 D/A 1 primary_doc.xml X0502 D/A LIVE 0001358877 LIMERICK BIOPHARMA INC 601 Gateway Boulevard, Suite 700 So. San Francisco CA 94080 650-742-0110 Efflux Technology, Inc. Limerick Neurosciences, Inc. CALIFORNIA Corporation true 2004 Wendye Robbins 601 Gateway Boulevard, Suite 700 So. San Francisco CA 94080 Executive Officer Director Asha Rajagopal 601 Gateway Boulevard, Suite 700 So. San Francisco CA 94080 Executive Officer Stephen Dow 601 Gateway Boulevard, Suite 700 So. San Francisco CA 94080 Director Corey Goodman 601 Gateway Boulevard, Suite 700 So. San Francisco CA 94080 Director Scott Minick 601 Gateway Boulevard, Suite 700 So. San Francisco CA 94080 Director Chad Waite 601 Gateway Boulevard, Suite 700 So. San Francisco CA 94080 Director Biotechnology Decline to Disclose 06 true 0001104659-09-043434 2009-07-14 false true true Series C Preferred Stock issued upon conversion of notes, accrued interest false 0 15380000 15380000 0 false 17 0 0 0 Funds to be used for working capital. false Limerick BioPharma, Inc. /s/ Ann Coppel Ann Coppel Sr. Legal Assistant 2009-08-20 -----END PRIVACY-ENHANCED MESSAGE-----